Press "Enter" to skip to content

The Finance Herald

Silexion Therapeutics Announces Additional Preclinical Success with SIL-204; Plans to Initiate Pre Clinical Trials for Colorectal Cancer

Silexion Therapeutics (NASDAQ: SLXN) has reported promising preclinical data for SIL-204, its next-generation siRNA candidate targeting KRAS mutations in pancreatic cancer. This announcement comes just days after the company revealed…